about
Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomasVariant classification in precision oncologyClassification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS AssessmentImmuno-oncology gene expression profiling of FFPE clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencingTesting NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assaysCombined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesTumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisionsProteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancerSerial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancerNext generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker stuSize matters: Dissecting key parameters for panel-based tumor mutational burden analysisIdentification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinomaNTRK testing: first results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysIntegrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryComparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndromeDistinct immune evasion in APOBEC-enriched, HPV-negative HNSCC
P50
Q48167974-E88FB282-4BBD-42DB-9DF7-1711FF412015Q48178985-9870F5E1-EF45-458C-AF1D-900769B586B8Q48201416-540B5A60-FE12-4FD0-9245-0F5D5D9B922AQ48238570-689A7CD6-7EA1-49F6-9CF9-84BD8BEFD382Q57797226-F6BABA26-6D9C-42F0-8723-257ED813F4E3Q90124514-6DB523A0-99CD-4269-A334-4AD11C1151ACQ90585399-FDA9E335-E661-4A9D-81B0-D4EDB71882E3Q90650604-135929E4-26D7-448E-A777-7726FEEAE829Q90943439-3BCD5C03-8AD0-4223-A6DF-F9F5716495EEQ91087874-B3995E9F-60E7-42B0-86FD-76A5CEF34954Q91140222-5D078371-D1F3-456A-865E-E9D65A5E1081Q91294510-F3C056EF-20B1-494F-8EF3-A0F6154A9EE3Q91384568-DDE1D4CD-D9E3-49E5-93F7-55470FF4A59BQ91533544-EB33821A-D704-48A2-B0F1-F7D297075C92Q91611771-3F2B3A06-3CBB-4793-81CB-3F994883D115Q91752191-2806B899-9D03-4DD9-A5A5-1938FD8E5435Q92142969-DF083BD1-55FF-47D2-A9A6-18788A158185Q92866584-BCF0E037-8875-4655-A833-A61093D542B3Q92961273-6EC5EF74-152D-4B32-AB27-B6F94259368AQ95939397-E8475841-6A87-463A-83A4-00E1FA446AFE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Albrecht Stenzinger
@ast
Albrecht Stenzinger
@en
Albrecht Stenzinger
@es
Albrecht Stenzinger
@nl
type
label
Albrecht Stenzinger
@ast
Albrecht Stenzinger
@en
Albrecht Stenzinger
@es
Albrecht Stenzinger
@nl
prefLabel
Albrecht Stenzinger
@ast
Albrecht Stenzinger
@en
Albrecht Stenzinger
@es
Albrecht Stenzinger
@nl
P106
P31
P496
0000-0003-1001-103X